OncoSec Medical Incorporated announced the appointment of Robert H. Arch as President. Dr. Arch was previously Head of Research at Elpiscience Biopharma Ltd. from October 2019 to June 2021, and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% |
|
-.--% | +9,900.00% |
2023 | Motion for Asset Sale Approved for OncoSec Medical Incorporated | CI |
2023 | Motion for Asset Sale Filed by OncoSec Medical Incorporated | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 596 | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- ONCS.Q Stock
- News OncoSec Medical Incorporated
- OncoSec Medical Incorporated Appoints Robert H. Arch as President